A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1

• Genomic alterations may improve diagnostic certainty and subsequent treatment of endometrial stromal sarcoma. • Novel JAZF1-BCORL1 mutation was identified. • Targeted therapeutics to down-stream targets may improve survival benefit in these patients.

Detalles Bibliográficos
Autores principales: Allen, Allison J, Ali, Siraj M., Gowen, Kyle, Elvin, Julia A., Pejovic, Tanja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348601/
https://www.ncbi.nlm.nih.gov/pubmed/28331900
http://dx.doi.org/10.1016/j.gore.2017.03.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348601/
https://www.ncbi.nlm.nih.gov/pubmed/28331900
http://dx.doi.org/10.1016/j.gore.2017.03.002

Ejemplares similares